Longevity Peptides
Which peptides are marketed for longevity, how strong the human evidence is, and how they compare with NAD+ and rapamycin.
Longevity peptides in 2026: the popular ones, why people use them, and how thin the human evidence really is
A sourced 2026 guide to longevity peptides: the popular ones (epitalon, MOTS-c, thymosin alpha-1, GHK-Cu), why people use them, an evidence-graded table that includes NAD+ precursors as the comparator, what is known about side effects and stacks, what they cost, and what the longevity community says.
NAD+ vs peptides for longevity: what the evidence says
A sourced, side-by-side comparison of NAD+ precursors (NMN and NR) and longevity peptides (MOTS-C, epitalon): what the human evidence actually supports, why blood NAD+ is a contested marker of aging, where 5-Amino-1MQ fits, how people stack them, and the honest next step for a healthspan goal.
Rapamycin vs peptides for longevity: what the evidence and side effects show
A sourced, side-by-side comparison of rapamycin (sirolimus) and research longevity peptides: what rapamycin is actually approved by the FDA for, why its longevity use is off-label and experimental, what the first human healthspan trial did and did not show, how it compares with peptides like MOTS-C and epitalon on evidence and side effects, and the honest next step.